Evolus (FRA:EVL) E10: €-1.81 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:EVL Evolus Inc FRA:EVL
73 GF Score
Price €7.08
GF Value €11.25
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Evolus E10?

Evolus FRA:EVL -3.09% 73 E10 is €-1.81 as of Jun. 2026. GuruFocus rates FRA:EVL with a GF Score™ of 73/100 and a GF Value™ of €11.25 (Possible Value Trap). The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Evolus's adjusted earnings per share data for the three months ended in Jun. 2026 was €-0.104. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-1.81 for the trailing ten years ended in Jun. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-08-22), Evolus's current stock price is €7.082. Evolus's E10 for the quarter that ended in Jun. 2026 was €-1.81. Evolus's Shiller PE Ratio of today is .


Evolus  (FRA:EVL) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Evolus E10 Related Terms


Evolus E10 Historical Data

* Premium members only.

The historical data trend for Evolus's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Evolus E10 Chart

Evolus Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Evolus Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -1.81

FRA:EVL vs EBS, ELTP, AKBA: E10 Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Evolus's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Evolus Shiller PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Evolus's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Evolus's Shiller PE Ratio falls into.


FRA:EVL
73GF Score
Evolus Inc FRA:EVL
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Evolus E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Evolus's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-0.104/333.9520*333.9520
=-0.104

Current CPI (Jun. 2026) = 333.9520.

Evolus Quarterly Data

per share eps CPI Adj_EPS
201512 0.000 236.525 0.000
201612 -0.191 241.432 -0.264
201703 -0.201 243.801 -0.275
201706 -0.110 244.955 -0.150
201709 -0.119 246.819 -0.161
201712 0.159 246.524 0.215
201803 -0.243 249.554 -0.325
201806 -0.591 251.989 -0.783
201809 -0.411 252.439 -0.544
201812 -0.404 251.233 -0.537
201903 -0.354 254.202 -0.465
201906 -1.212 256.143 -1.580
201909 -0.890 256.759 -1.158
201912 -0.423 256.974 -0.550
202003 -0.534 258.115 -0.691
202006 -0.559 257.797 -0.724
202009 -0.289 260.280 -0.371
202012 -2.696 260.474 -3.457
202103 0.134 264.877 0.169
202106 -0.257 271.696 -0.316
202109 -0.298 274.310 -0.363
202112 -0.292 278.802 -0.350
202203 -0.281 287.504 -0.326
202206 -0.397 296.311 -0.447
202209 -0.364 296.808 -0.410
202212 -0.217 296.797 -0.244
202303 -0.243 301.836 -0.269
202306 -0.295 305.109 -0.323
202309 -0.281 307.789 -0.305
202312 -0.193 306.746 -0.210
202403 -0.202 312.332 -0.216
202406 -0.167 314.175 -0.178
202409 -0.270 315.301 -0.286
202412 -0.105 315.605 -0.111
202503 -0.277 319.799 -0.289
202506 -0.234 322.561 -0.242
202509 -0.204 324.800 -0.210
202512 0.000 324.054 0.000
202603 -0.138 330.213 -0.140
202606 -0.104 333.952 -0.104

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of €-1.81 mean?
Evolus (FRA:EVL) has a E10 of €-1.81 as of Jun. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Evolus and its competitors.
Is Evolus' E10 too high?
Evolus' current E10 is €-1.81. Overall, Evolus has a GF Score™ of 73/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Evolus' E10 compare to EBS and ELTP?
Evolus' E10 of €-1.81 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Drug Manufacturers company?
A good E10 depends on the Drug Manufacturers industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Evolus and its competitors. Evolus's current E10 is €-1.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evolus stock overvalued right now?
Based on GuruFocus' analysis, Evolus (FRA:EVL) is currently considered Possible Value Trap. The stock's GF Value™ is €11.25, compared to a current price of €7.08 — trading 37% below its estimated fair value. The current E10 is €-1.81. Evolus' overall GF Score™ is 73/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Evolus (FRA:EVL), the current E10 is €-1.81 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Evolus (FRA:EVL) Overvalued in 2026?

Based on GuruFocus' analysis, Evolus stock appears to be undervalued. The current stock price of €7.08 is trading 37% below its estimated GF Value™ of €11.25. GuruFocus considers Evolus to be Possible Value Trap.

Key valuation signals for FRA:EVL:

  • E10: €-1.81
  • GF Value™: €11.25 vs. price of €7.08 (37% below fair value)
  • GF Score™: 73/100 with 7 warning signs

No single metric tells the full story. See the FRA:EVL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Evolus Business Description

Other Exchanges EOLS:USAEVL:Germany
Address 520 Newport Center Drive, Suite 1200, Newport Beach, CA, USA, 92660
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.
73GF Score

Get the complete analysis for FRA:EVL

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€7.08
Price
€11.25
GF Value